scholarly journals The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study

2021 ◽  
Author(s):  
Tommaso Cai ◽  
Luca Gallelli ◽  
Erika Cione ◽  
Gianpaolo Perletti ◽  
Francesco Ciarleglio ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Symptoms ◽  
Clinical Status ◽  
Well Being ◽  
Antibiotic Use ◽  
Chronic Bacterial Prostatitis ◽  
Symptomatic Recurrence ◽  
Bacterial Prostatitis ◽  
Phase Iv

Abstract Purpose To evaluate the efficacy of Lactobacillus paracasei CNCM I-1572 (L. casei DG®) in both prevention of symptomatic recurrences and improvement of quality of life in patients with chronic bacterial prostatitis (CBP). Methods Patients with CBP attending a single Urological Institution were enrolled in this phase IV study. At enrollment, all patients were treated with antibiotics in agreement with EAU guidelines and then were treated with L. casei DG® (2 capsules/day for 3 months). Clinical and microbiological analyses were carried out before (enrollment, T0) and 6 months (T2) after the treatment. Both safety and adherence to the treatment were evaluated 3 months (T1) after the enrollment. NIH Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS) and Quality of Well-Being (QoL) questionnaires were used. The outcome measures were the rate of symptomatic recurrence, changes in questionnaire symptom scores and the reduction of antibiotic use. Results Eighty-four patients were included. At T2, 61 patients (72.6%) reported a clinical improvement of symptoms with a return to their clinical status before symptoms. A time dependent improvement in clinical symptoms with significant changes in NIH-CPSI, IPSS and QoL (mean difference T2 vs T0: 16.5 ± 3.58; − 11.0 ± 4.32; + 0.3 ± 0.09; p < 0.001), was reported. We recorded that L. casei DG® treatment induced a statistically significant decrease in both (p < 0.001) symptomatic recurrence [1.9/3 months vs 0.5/3 months] and antibiotic use [− 7938 UDD]. No clinically relevant adverse effects were reported. Conclusions L. casei DG® prevents symptomatic recurrences and improves the quality of life in patients with CBP, reducing the antibiotic use.

Bio-identical hormones replacement therapy and the quality of life for breast cancer patients.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 87-87
Author(s):  
TS Wiley
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Replacement Therapy ◽  
Clinical Symptoms ◽  
Hormone Replacement ◽  
Well Being ◽  
Normal Serum ◽  
Breast Cancer Patients ◽  
The Impact

87 Background: Many treatments for breast cancer block the estrogen receptor or the androgen conversion of estrogen to reduce the risk of relapse. This results in a change in the hormonal milieu. Although most women tolerate the change in hormonal status, problems can arise from this change. Without estrogen, clinical symptoms include hot flashes, sleeplessness, insulin sensitivity, and mood changes. Here, it is examined that the use of estrogen and progesterone bio-identical hormone replacement therapy (BHRT) for women in the normal physiological pattern of reproductive women is expected to coincide with increased well-being and better quality of life for women with breast cancer. Methods: This BHRT approach uses bio-identical estrogen and progesterone to restore the woman’s body to normal serum levels through twice daily transdermal application. Using real “bio-identical” or plant-derived human molecular hormones compounded via a standard formula, concentration, and packaging of transdermal creams (Estradiol E2) of 1 mg/0.1ml and progesterone P4 of 20 mg/0.1 ml). Furthermore, through an understanding of hormonal mechanisms, this BHRT mimics the female reproductive cycle by following a 28 day cycle. Results: Throughout the study, women were asked to how gauge their general well-being and quality of life. Most women reported resolution of menopausal symptoms, better sleep, decreased migraines and incontinence, increased focus, and increased libido. Most patients were pleased to be on the treatment and showed general improvement in the quality of life. Conclusions: We present the general mechanisms of action for BHRT and explain clinical trials conducted over the past decade have been examining the impact on the overall well-being and quality of life for 112 patients, as well as the impact on various cancers as well as other chronic conditions. Patients reported increased energy and overall well-being. BHRT provided resolution of most all of the patients subjective anti-estrogenic complaints. It is also observed that the recurrence rate of various breast cancers was no higher than national averages. Therefore, BHRT and rhythmic dosing seems to greatly improve well-being with no increase of cancer risk.

Health-related quality of life in adolescents with congenital heart disease

2014 ◽  
Vol 25 (3) ◽  
pp. 526-532 ◽  
Author(s):  
Juliana Bertoletti ◽  
Giovana C. Marx ◽  
Sérgio P. Hattge ◽  
Lúcia C. Pellanda
Keyword(s):  
Quality Of Life ◽  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Clinical Symptoms ◽  
Well Being ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

AbstractPurpose: This study aims to evaluate the health-related quality of life of adolescents with congenital heart disease, describing health-related quality of life according to the diagnosis and severity of congenital heart disease, identified by variables such as the presence of symptoms, surgical interventions, use of medication, and residual lesion. Methods: A cross-sectional study was conducted on 203 adolescents with congenital heart disease attended at the Pediatric Cardiology ambulatory of a reference hospital in Brazil. The Brazilian version of the questionnaire KIDSCREEN-27 was used for the assessment of health-related quality of life. Information related to the congenital heart disease diagnosis and clinical variables were collected from the medical records of the patients. Results: There was no statistically significant difference between acyanotic and cyanotic groups, as well as for the different diagnosis of congenital heart disease. A trend for better health-related quality of life in the dimension of Psychological Well-Being (p=0.054) was found in the groups with surgical intervention and use of medication. Adolescents that referred a good general health presented significantly better results in all dimensions of health-related quality of life, except for Autonomy and Parent Relation, than those who presented clinical symptoms (p<0.05). Conclusions: Type of congenital heart disease and initial diagnosis did not seem to affect the perception of health-related quality of life, corroborating findings of several studies. Surgical interventions and the use of medication can improve previous clinical status, and therefore it seems to be beneficial in terms of Psychological Well-Being. The presence of clinical symptoms was the variable that caused the largest impact on the perception of health-related quality of life, possibly because of the impairment they bring to the daily lives of these patients.

scholarly journals Cultural adaptation of the Polish version of the PAH-SYMPACT questionnaire (PL)

2021 ◽  
Author(s):  
Kathie Sarzyńska ◽  
Jacek Polański ◽  
Grzegorz Kopeć ◽  
Ewa Mroczek ◽  
Beata Jankowska-Polańska
Keyword(s):  
Quality Of Life ◽  
Internal Consistency ◽  
Clinical Status ◽  
Psychometric Evaluation ◽  
Well Being ◽  
World Health ◽  
Retest Reliability ◽  
Polish Version ◽  
Test Retest Reliability

Abstract Background: Pulmonary arterial hypertension (PAH) is a rare chronic disease that significantly affects patients' ability to perform daily activities, decreasing physical and mental well-being and social functioning. Symptoms of the disease increase as it progresses, leading to disability and death. In addition, the quality of life of patients deteriorates as the disease progresses and may reflect the effectiveness of the therapy used. Most questionnaires used in PAH clinical trials are generic quality-of-life (QoL) measures that may do not adequately reflect the clinical status and symptoms, changes in health status, or prognosis of patients with PAH. The purpose of this study was to translate and culturally adapt the Polish version of the PAH-SYMPACT questionnaire to reflect the severity of symptoms and their effects on patients’ daily functioning. Material and methods: The study included 55 patients with PAH treated, as part of a pulmonary hypertension treatment program in Poland. Validation of this questionnaire met the guidelines for translation and validation of questionnaires, which are set out in the document on the process of translation and adaptation of World Health Organization tools. Reliability was tested using a measure of internal consistency (Cronbach's α) and test-retest reliability. Correctness was confirmed using known group validity.Results: Moderate internal consistency (Cronbach's) was found for all questionnaire domains (cardiopulmonary symptoms α=0.706; cardiovascular symptoms α=0.806, physical effects α=0.904, psychological effects α=0.817) and test-retest reliability was satisfactory. The PAH-SYMPACT questionnaire (PL) met all validation criteria and can be used to assess quality of life in patients with PAH.Conclusion: Psychometric evaluation of the Polish version of the PAH-SYMPACT (PL) indicates that it is a reliable and valid measure tool to detect quality of life patients with PAH.

scholarly journals Daidzein plus isolase associated with zinc improves clinical symptoms and quality of life in patients with LUTS due to benign prostatic hyperplasia: Results from a phase I-II study

2017 ◽  
Vol 89 (1) ◽  
pp. 12 ◽  
Author(s):  
Daniele Tiscione ◽  
Luca Gallelli ◽  
Irene Tamanini ◽  
Lorenzo Giuseppe Luciani ◽  
Paolo Verze ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Benign Prostatic Hyperplasia ◽  
Phase I ◽  
Clinical Symptoms ◽  
Statistical Significance ◽  
Well Being ◽  
Prostatic Hyperplasia ◽  
International Prostatic Symptom Score ◽  
Significant Difference

Objective: In the last years there is a growing interest in nutraceutical substances that seems able to improve clinical symptoms in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). In this paper, we evaluated both efficacy and safety of a combination of daidzein with isolase and zinc in patients with LUTS due to BPH. Materials and methods: In a phase I-II study clinical trial we enrolled patients with clinical and instrumental diagnosis of LUTS associated to BPH that received a six-month treatment with a combination of daidzein with isolase and zinc (1 tablet/day). Clinical, laboratory and instrumental analyses were carried out at the time of admission (T0) and 6 months after the ending of the treatment (T1). The Italian version of International Prostatic Symptom Score (IPSS), International Index of Erectile Function (IIEF-5) and Quality of Well-Being (QoL) questionnaires were used. The development of adverse drug reactions (ADRs) and drug interactions (DDIs) were recorded using the Naranjo scale and drug interaction probability scale. Student’s t test and Anova test were used for statistical analysis, and the threshold of statistical significance was set at P &lt; 0.05. Results: We enrolled 71 patients, 62 (87.3%) completed the follow-up and we documented a significant differences between T0 and T1 in terms of IPSS [21.5 ± 1.2 vs 16.2 ± 1.5; (-4.8); p &lt; 0.001], Cmax [9.7 ± 3.7 vs 15.3 ± 2.5; (+5.6); p &lt; 0.001] and QoL [0.56 ± 0.15 vs 0.84 ± 0.19; (+0.28); p &lt; 0.001]. In contrast, no significant difference were recorded in terms of IIEF-5 [p = 0.50] and PSA [p = 0.67]. Finally, we did not record any significant ADRs or DDIs during the study. Conclusions: In this study, we documented that a combination of daidzein with isolase and zinc, reduces the clinical symptoms of LUTS and improves the quality of life in patients with BPH, without the development of ADRs or DDIs.

scholarly journals Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study

2019 ◽  
Vol 14 (12) ◽  
pp. 1013-1021
Author(s):  
Tommaso Cai ◽  
Irene Tamanini ◽  
Andrea Cocci ◽  
Fabrizio di Maida ◽  
Patrizio Caciagli ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prospective Study ◽  
Medical Device ◽  
Clinical Improvement ◽  
Clinical Status ◽  
Antibiotic Use ◽  
Tract Infections ◽  
A Prospective Study

Aim: To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs). Patients & methods: Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological evaluations were performed at baseline and 1, 3 and 6 months from enrolment. Results: At first follow-up, 41 reported a clinical improvement and a return to their clinical status before UTI, while 47 and 51 did so at the second and third follow-up evaluations. A statistically significant clinical improvement was reported at each follow-up visit (quality of life [QoL] 94.2 vs 98.6; QoL 94.1 vs 98.7; QoL 94.2 vs 99.1; p < 0.001). A statistically significant reduction in antibiotic use was reported. Conclusion: This medical device is able to improve quality of life in women with rUTIs, reduce recurrences and antibiotic use.

scholarly journals Cultural adaptation of the Polish version of the PAH-SYMPACT questionnaire (PL)

2021 ◽  
Vol 20 (Supplement_1) ◽  
Author(s):  
K Sarzynska ◽  
J Polanski ◽  
G Kopec ◽  
E Mroczek ◽  
B Jankowska-Polanska
Keyword(s):  
Quality Of Life ◽  
Internal Consistency ◽  
Clinical Status ◽  
Psychometric Evaluation ◽  
Well Being ◽  
World Health ◽  
Retest Reliability ◽  
Polish Version ◽  
Test Retest Reliability

Abstract Funding Acknowledgements Type of funding sources: None. Background Pulmonary arterial hypertension (PAH) is a rare chronic disease that significantly affects patients" ability to perform daily activities, decreasing physical and mental well-being and social functioning. Symptoms of the disease increase as it progresses, leading to disability and death. In addition, the quality of life of patients deteriorates as the disease progresses and may reflect the effectiveness of the therapy used. Most questionnaires used in PAH clinical trials are generic quality-of-life (QoL) measures that may do not adequately reflect the clinical status and symptoms, changes in health status, or prognosis of patients with PAH. Purpose The purpose of this study was to translate and culturally adapt the Polish version of the PAH-SYMPACT questionnaire to reflect the severity of symptoms and their effects on daily functioning. Material and methods The study included 55 patients with PAH treated, as part of a pulmonary hypertension treatment program in Poland. Patients were asked to complete the PAH-SYMPACT questionnaire. After about 2 weeks, a follow-up was carried out. Validation of this questionnaire met the guidelines for translation and validation of questionnaires, which are set out in the document on the process of translation and adaptation of World Health Organization tools.  Reliability was tested using a measure of internal consistency (Cronbach"s α) and test-retest reliability. Correctness was confirmed using known group validity. Results Moderate internal consistency (Cronbach"s) was found for all questionnaire domains (cardiopulmonary symptoms α=0.706; cardiovascular symptoms α=0.806, physical effects α=0.904, psychological effects α=0.817) and test-retest reliability was satisfactory. The PAH-SYMPACT questionnaire (PL) met all validation criteria and can be used to assess quality of life in patients with PAH. Conclusion Psychometric evaluation of the Polish version of the PAH-SYMPACT (PL) indicates that it is a reliable and valid measure tool to detect quality of life patients with PAH.

Perceived Overprotection and Its Association With Quality of Life in Dementia

GeroPsych ◽  
2019 ◽  
Vol 32 (3) ◽  
pp. 125-134
Author(s):  
Mechthild Niemann-Mirmehdi ◽  
Andreas Häusler ◽  
Paul Gellert ◽  
Johanna Nordheim
Keyword(s):  
Quality Of Life ◽  
Patient Autonomy ◽  
Positive Association ◽  
Well Being ◽  
Negative Association ◽  
Significant Positive Association ◽  
Cross Sectional ◽  
People With Dementia ◽  
Mental Well Being

Abstract. To date, few studies have focused on perceived overprotection from the perspective of people with dementia (PwD). In the present examination, the association of perceived overprotection in PwD is examined as an autonomy-restricting factor and thus negative for their mental well-being. Cross-sectional data from the prospective DYADEM study of 82 patient/partner dyads (mean age = 74.26) were used to investigate the association between overprotection, perceived stress, depression, and quality of life (QoL). The analyses show that an overprotective contact style with PwD has a significant positive association with stress and depression, and has a negative association with QoL. The results emphasize the importance of avoiding an overprotective care style and supporting patient autonomy.

Sign in / Sign up

Export Citation Format

Share Document